NEW YORK (GenomeWeb News) – Response Genetics today announced the execution of a provider contract with Blue Cross and Blue Shield of Illinois, providing the health plan's 7.4 million members coverage for the Los Angeles-based molecular diagnostics firm's tests.

Response Genetics offers molecular predictive tests for lung, colon, gastric, and melanoma cancers, as well as tests for detecting EGFR, KRAS, and other mutations. Its tests, the firm said, help physicians determine which treatments may be best for each individual patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.